110. Development and Characterization of Targeted Lentiviral Vectors Pseudotyped With the Tupaia Paramyxovirus Glycoproteins

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)36682-5
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Elsevier BV

Related search

112. Assessing Potency in Lentiviral Vectors Pseudotyped With VSV-G, RD114 or FV Envelope Glycoproteins

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2011English

547. A Simple and Scalable Method to Concentrate Measles-Pseudotyped Lentiviral Vectors

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Pseudotyping Lentiviral Vectors With the Wild-Type Measles Virus Glycoproteins Improves Titer and Selectivity

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2009English

Targeted Lentiviral Vectors: Current Applications and Future Potential

2013English

366. Development of Engineered Magnetic Nanoparticles Coupled With Lentiviral Vectors for Targeted Cancer Therapy and Hyperthermia

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2015English

Development of an Avian Leukosis-Sarcoma Virus Subgroup a Pseudotyped Lentiviral Vector

Journal of Virology
Insect ScienceImmunologyMicrobiologyVirology
2001English

59. Developing Lentiviral Vectors for Targeted Gene Delivery in Vivo

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

1. Measles Virus Glycoprotein Pseudotyped Lentiviral Vectors Transduce Cytokine Stimulated and Resting Hematopoietic Stem Cells at an Efficiency Without Precedent

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2015English

Development of Gene Therapy for Hematopoietic Stem Cells Using Lentiviral Vectors

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2002English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy